Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access Poster presentation

Economic impact of an increased incidence of invasive mold infections (IMI)

C Van Delden1*, A Iten2, A Gayet-Ageron2, V Camus2, Y Martin2, Y Chalandon3 and D Pittet2

  • * Corresponding author: C Van Delden

Author Affiliations

1 Service of Infectious Diseases, HUG, Genève, Switzerland

2 Infection Control Program, HUG, Genève, Switzerland

3 Service of Haematology, HUG, Genève, Switzerland

For all author emails, please log on.

BMC Proceedings 2011, 5(Suppl 6):P51  doi:10.1186/1753-6561-5-S6-P51

The electronic version of this article is the complete one and can be found online at:

Published:29 June 2011

© 2011 Van Delden et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction / objectives

In July 2010, an increase of IMI was observed in patients with leukemia and bone marrow transplantation admitted to the hematology wards at the University of Geneva Hospitals.


We conducted a retrospective survey which identified 6 cases of IMI (3 possible and 3 probable) in 2009 and 18 (9 possible, 7 probable and 2 proven) in 2010. All cases occurred during chemotherapy for acute leukemia, allogeneic hematopoietic stem cell transplantation or graft versus host disease. The incidence of nosocomial IMI among the at risk population was 3.6 fold higher in 2010 than in 2009.

We aimed to identify any potential failures in the care of at-risk patients. Additional preventive measures were set up for isolation rooms and their cleansing, and also their computer equipment. Protective measures were instituted for the patients (masks, gowns, caps, food, objects made available for the patients, transportation). Standard antifungal prophylaxis was changed from fluconazole 100 mg/d to voriconazole 400 mg/d.


The costs of the various preventive measures to stop the occurrence of new fungal infections were estimated at 2'500'000 CHF (1'900'000 Euros) covering the period from June, 2010 to June, 2011. This represented an average of 22’600 CHF (17’176 Euros) per patient admitted. Of note, 31% of the costs were associated with the change in antifungal prophylaxis.

To date no new cases have been reported since the introduction of these measures.


A supplementary review is in progress in order to quantify the overall impact of the preventive measures taken and to decide which measures should be continued.

Disclosure of interest

None declared.